Select therapeutic use:
Indications for MACUGEN:
Treatment of neovascular (wet) age-related macular degeneration.
Give by intravitreous inj. 0.3mg once every 6 weeks into the eye to be treated.
Ocular or periocular infections.
Monitor for infection during week following inj (endophthalmitis possible). Monitor intraocular pressure and perfusion of optic nerve. Pregnancy (Cat.B). Nursing mothers.
Vascular endothelial growth factor (VEGF) inhibitor.
Anterior chamber inflammation, blurred vision, cataract, conjunctival hemorrhage, corneal edema, eye discharge, eye irritation, eye pain, hypertension, increased intraocular pressure, ocular discomfort, punctate keratitis, reduced visual acuity, visual disturbances, vitreous floaters, vitreous opacities, blepharitis, conjunctivitis, photopsia, bronchitis, diarrhea, dizziness, headache, nausea, UTI, others.